{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:55:25Z","timestamp":1784940925308,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12325-018-0859-x","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T15:49:13Z","timestamp":1545925753000},"page":"278-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7124-2096","authenticated-orcid":false,"given":"Stefano","family":"Omboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"859_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459\u20131544.","DOI":"10.1016\/S0140-6736(16)31012-1"},{"issue":"2","key":"859_CR2","first-page":"634","volume":"2014","author":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration","year":"2014","unstructured":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2014(2):634\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"859_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"859_CR4","doi-asserted-by":"crossref","unstructured":"Williams B, Mancia G, Spiering W, et al.. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/HYPERTENSIONAHA.116.08485","volume":"69","author":"AH Katsanos","year":"2017","unstructured":"Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 2017;69:171\u20139.","journal-title":"Hypertension"},{"key":"859_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","volume":"116","author":"A Zanchetti","year":"2015","unstructured":"Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res. 2015;116:1058\u201373.","journal-title":"Circ Res"},{"key":"859_CR8","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk\u2013overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305\u201314.","DOI":"10.1097\/HJH.0000000000000380"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10\u2014should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922\u201344.","journal-title":"J Hypertens"},{"key":"859_CR10","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels\u2014updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613\u201322.","DOI":"10.1097\/HJH.0000000000000881"},{"key":"859_CR11","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150\u201360.","DOI":"10.1097\/HJH.0000000000001547"},{"key":"859_CR12","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u2013115.","journal-title":"Hypertension"},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1161\/CIRCULATIONAHA.110.983874","volume":"123","author":"IM Kronish","year":"2011","unstructured":"Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611\u201321.","journal-title":"Circulation"},{"key":"859_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0004867417721654","volume":"52","author":"DJ Brownstein","year":"2018","unstructured":"Brownstein DJ, Salagre E, K\u00f6hler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: a meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018;52:24\u201338.","journal-title":"Aust N Z J Psychiatry"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/jch.13108","volume":"19","author":"Z Li","year":"2017","unstructured":"Li Z, Li Y, Liu Y, Xu W, Wang Q. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: a network meta-analysis. J Clin Hypertens (Greenwich). 2017;19:1348\u201356.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"859_CR16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7555\/JBR.29.20140149","volume":"29","author":"D Zhao","year":"2015","unstructured":"Zhao D, Wang ZM, Wang LS. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29:475\u201385.","journal-title":"J Biomed Res"},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","volume":"55","author":"MP Schneider","year":"2010","unstructured":"Schneider MP, Hua TA, B\u00f6hm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299\u2013307.","journal-title":"J Am Coll Cardiol"},{"key":"859_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/eurheartj\/ehr400","volume":"33","author":"FA McAlister","year":"2012","unstructured":"McAlister FA, Renin Angiotension System Modulator Meta-Analysis Investigators. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J. 2012;33:505\u201314.","journal-title":"Eur Heart J"},{"key":"859_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00125-011-2398-8","volume":"55","author":"P Vejakama","year":"2012","unstructured":"Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55:566\u201378.","journal-title":"Diabetologia"},{"key":"859_CR20","doi-asserted-by":"publisher","first-page":"f6008","DOI":"10.1136\/bmj.f6008","volume":"347","author":"HY Wu","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.","journal-title":"BMJ"},{"key":"859_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","volume":"148","author":"DB Matchar","year":"2008","unstructured":"Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16\u201329.","journal-title":"Ann Intern Med"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s11606-011-1938-8","volume":"27","author":"BJ Powers","year":"2012","unstructured":"Powers BJ, Coeytaux RR, Dolor RJ, et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2012;27:716\u201329.","journal-title":"J Gen Intern Med"},{"key":"859_CR23","doi-asserted-by":"crossref","unstructured":"Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;(8):CD009096.","DOI":"10.1002\/14651858.CD009096.pub2"},{"key":"859_CR24","first-page":"49","volume":"45","author":"P K\u0131z\u0131l\u0131rmak","year":"2017","unstructured":"K\u0131z\u0131l\u0131rmak P, \u00dcresin Y, \u00d6zdemir O, K\u0131l\u0131\u00e7k\u0131ran Avc\u0131 B, Tokg\u00f6zo\u011flu L, \u00d6ngen Z. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Turk Kardiyol Dern Ars. 2017;45:49\u201366.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"859_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","volume":"91","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91:51\u201360.","journal-title":"Mayo Clin Proc"},{"key":"859_CR26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC Vark van","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088\u201397.","journal-title":"Eur Heart J"},{"key":"859_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","volume":"61","author":"G Savarese","year":"2013","unstructured":"Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"859_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1177\/2047487317728766","volume":"24","author":"GL Salvador","year":"2017","unstructured":"Salvador GL, Marmentini VM, Cosmo WR, Junior EL. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1914\u201324.","journal-title":"Eur J Prev Cardiol"},{"key":"859_CR29","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.116.025950","volume":"135","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Bangalore S. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 2017;135:2085\u20137.","journal-title":"Circulation"},{"key":"859_CR30","doi-asserted-by":"crossref","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","DOI":"10.1056\/NEJMoa0801317"},{"issue":"Suppl. 1","key":"859_CR31","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/HJH.0b013e32835d2b05","volume":"31","author":"A Sierra de la","year":"2013","unstructured":"de la Sierra A, Volpe M. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. J Hypertens. 2013;31(Suppl. 1):S13\u20137.","journal-title":"J Hypertens"},{"key":"859_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/HJH.0b013e32832961ed","volume":"27","author":"M Volpe","year":"2009","unstructured":"Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens. 2009;27:941\u20136.","journal-title":"J Hypertens"},{"key":"859_CR33","doi-asserted-by":"publisher","first-page":"d2234","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.","journal-title":"BMJ"},{"key":"859_CR34","doi-asserted-by":"crossref","unstructured":"Potier L, Roussel R, Elbez Y, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017;103:1339\u201346.","DOI":"10.1136\/heartjnl-2016-310705"},{"key":"859_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1524-6175.2007.07182.x","volume":"9","author":"PC Stafylas","year":"2007","unstructured":"Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens (Greenwich). 2007;9:751\u20139.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"859_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","volume":"3","author":"B Wang","year":"2015","unstructured":"Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:263\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"859_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40256-013-0058-8","volume":"14","author":"CA D\u00e9zsi","year":"2014","unstructured":"D\u00e9zsi CA. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs. 2014;14:167\u201373.","journal-title":"Am J Cardiovasc Drugs"},{"key":"859_CR38","doi-asserted-by":"crossref","unstructured":"Omboni S, Malacco E, Mallion JM, Fabrizzi P, Volpe M. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies. High Blood Press Cardiovasc Prev. 2014;21:1\u201319.","DOI":"10.1007\/s40292-013-0037-9"},{"key":"859_CR39","doi-asserted-by":"crossref","unstructured":"Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A, Study Group. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens. 2012;30:1468\u201377.","DOI":"10.1097\/HJH.0b013e32835466ac"},{"key":"859_CR40","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/CIA.S88195","volume":"10","author":"S Omboni","year":"2015","unstructured":"Omboni S, Malacco E, Mallion JM, Volpe M. Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. Clin Interv Aging. 2015;10:1575\u201386.","journal-title":"Clin Interv Aging"},{"key":"859_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s12325-013-0076-6","volume":"30","author":"L Ruilope","year":"2013","unstructured":"Ruilope L, Schaefer A. The fixed-dose combination of olmesartan\/amlodipine was superior in central aortic blood pressure reduction compared with perindopril\/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30:1086\u201399.","journal-title":"Adv Ther"},{"key":"859_CR42","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/jch.12673","volume":"18","author":"LM Ruilope","year":"2016","unstructured":"Ruilope LM, SEVITENSION Study Investigators. Fixed-combination olmesartan\/amlodipine was superior to perindopril\u2009+\u2009amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016;18:528\u201335.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"859_CR43","doi-asserted-by":"crossref","unstructured":"Redon J, Pichler G, Missed Dose Study Group. Comparative study of the efficacy of olmesartan\/amlodipine vs. perindopril\/amlodipine in peripheral and central blood pressure parameters after missed dose in type 2 diabetes. Am J Hypertens. 2016;29:1055\u201362.","DOI":"10.1093\/ajh\/hpw033"},{"key":"859_CR44","doi-asserted-by":"crossref","unstructured":"Redon J, Pichler G, Missed Dose Study Group. Comparative study of the efficacy of olmesartan\/amlodipine vs. perindopril\/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34:359\u201367.","DOI":"10.1097\/HJH.0000000000000793"},{"key":"859_CR45","doi-asserted-by":"crossref","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34:1921\u201332.","DOI":"10.1097\/HJH.0000000000001052"},{"key":"859_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/TCRM.S25976","volume":"7","author":"S Omboni","year":"2011","unstructured":"Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag. 2011;7:459\u201371.","journal-title":"Ther Clin Risk Manag"},{"key":"859_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjmed.2014.07.011","volume":"128","author":"S Bezalel","year":"2015","unstructured":"Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. Am J Med. 2015;128:120\u20135.","journal-title":"Am J Med"},{"key":"859_CR48","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"859_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/eurheartj\/ehq382","volume":"32","author":"M Volpe","year":"2011","unstructured":"Volpe M, Azizi M, Danser AH, Nguyen G, Ruilope LM. Twisting arms to angiotensin receptor blockers\/antagonists: the turn of cancer. Eur Heart J. 2011;32:19\u201322.","journal-title":"Eur Heart J"},{"key":"859_CR50","doi-asserted-by":"publisher","first-page":"E1073","DOI":"10.1503\/cmaj.101497","volume":"183","author":"C Yoon","year":"2011","unstructured":"Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011;183:E1073\u201384.","journal-title":"CMAJ"},{"key":"859_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1074248415619490","volume":"21","author":"S Chaugai","year":"2016","unstructured":"Chaugai S, Meng WY, Ali Sepehry A. Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2016;21:388\u2013404.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"859_CR52","first-page":"448","volume":"17","author":"M Al-Mallah","year":"2010","unstructured":"Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J. 2010;17:448\u201356.","journal-title":"Cardiol J"},{"key":"859_CR53","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10654-017-0285-4","volume":"32","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. Eur J Epidemiol. 2017;32:947\u201359.","journal-title":"Eur J Epidemiol"},{"key":"859_CR54","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.hlc.2017.06.721","volume":"27","author":"B Tsoi","year":"2017","unstructured":"Tsoi B, Akioyamen LE, Bonner A, et al. Comparative efficacy of angiotensin II antagonists in essential hypertension: systematic review and network meta-analysis of randomised controlled trials. Heart Lung Circ. 2017;27:666\u201382.","journal-title":"Heart Lung Circ"},{"key":"859_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","volume":"50","author":"N Burbure","year":"2016","unstructured":"Burbure N, Lebwohl B, Arguelles-Grande C, Green PH, Bhagat G, Lagana S. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127\u201334.","journal-title":"Hum Pathol"},{"key":"859_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/apt.14176","volume":"46","author":"M Zanelli","year":"2017","unstructured":"Zanelli M, Negro A, Santi R, et al. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment Pharmacol Ther. 2017;46:471\u20133.","journal-title":"Aliment Pharmacol Ther"},{"key":"859_CR57","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.5858\/arpa.2015-0204-RA","volume":"139","author":"EY Choi","year":"2015","unstructured":"Choi EY, McKenna BJ. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med. 2015;139:1242\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"859_CR58","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Ripellino C, Cataldo N. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Pharmacoepidemiol Drug Saf. 2018;27:581\u201386.","DOI":"10.1002\/pds.4402"},{"key":"859_CR59","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/14740338.2017.1376647","volume":"16","author":"N Bortoli De","year":"2017","unstructured":"De Bortoli N, Ripellino C, Cataldo N, Marchi S. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. Expert Opin Drug Saf. 2017;16:1221\u20135.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0859-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0859-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0859-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:29:29Z","timestamp":1694525369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0859-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0859-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,27]]},"assertion":[{"value":"2 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}